M. Shimakawa

R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

Papers (4)

• 2017
  Probiotic Bifidobacterium bifidum G9‐1 attenuates 5‐fluorouracil‐induced intestinal mucositis in mice via suppression of dysbiosis‐related secondary inflammatory responses10.1111/1440-1681.12792
• 2017
  Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors10.1371/journal.pone.0173979
• 2010
  Effects of Bifidobacterium bifidum G9-1 on Nasal Symptoms in a Guinea Pig Model of Experimental Allergic Rhinitis10.12938/bifidus.30.1
• 2005
  Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice.10.1248/BPB.28.1462